Funda Meric‐Bernstam
The University of Texas MD Anderson Cancer Center · 2,871 works · 105,984 citations · h-index 147
Top works
- The Immune Landscape of Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- PD-L1 Expression in Triple-Negative Breast Cancer
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
- Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
- Clonal evolution in breast cancer revealed by single nucleus genome sequencing
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller
- Targeting the mTOR Signaling Network for Cancer Therapy
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes